3-Aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds, and pharmaceutical composition containing the same

Information

  • Patent Grant
  • 4874773
  • Patent Number
    4,874,773
  • Date Filed
    Tuesday, August 30, 1988
    36 years ago
  • Date Issued
    Tuesday, October 17, 1989
    35 years ago
Abstract
Novel 3-aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.3.5 alkynyl, C.sub.3-8 cycloalkyl, R.sup.2 is C.sub.1-10 alkyl, and the NO.sub.2 group is substituted at ortho- or meta-position, provided that when the NO.sub.2 group is substituted at ortho-position and R.sup.2 is methyl, R.sup.1 is C.sub.3-5 alkyl, C.sub.2-5 alkenyl, C.sub.3-5 alkynyl, or C.sub.3-8 cycloalkyl, and when the NO.sub.2 group is substituted at meta-position and R.sup.1 is H, R.sup.2 is C.sub.3-10 alkyl, which have excellent hypotensive, vasodilating activities and are useful for the prophylaxis and treatment of hypertension, ischemic heart diseases and cerebral and peripheral circulation diseases.
Description

This invention relates to novel 3-aminocarbonyl-4-dihydropyridine-5-carboxylic acid compounds, processes for the preparation thereof, and a pharmaceutical composition containing the same. More particularly, it relates to 3-aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds of the formula: ##STR2## wherein R.sup.1 is hydrogen atom, an alkyl having 1 to 5 carbon atoms, an alkenyl having 2 to 5 carbon atoms, an alkynyl having 3 to 5 carbon atoms, or a cycloalkyl having 3 to 8 carbon atoms, R.sup.2 is an alkyl having 1 to 10 carbon atoms, and the NO.sub.2 group is substituted at ortho- or meta-position, provided that when the NO.sub.2 group is substituted at ortho-position and R.sup.2 is methyl, R.sup.1 is an alkyl having 3 to 5 carbon atoms, an alkenyl having 2 to 5 carbon atoms, an alkynyl having 3 to 5 carbon atoms, or a cycloalkyl having 3 to 8 carbon atoms, and when the NO.sub.2 group is substituted at meta-position and R.sup.1 is hydrogen atom, R.sup.2 is an alkyl having 3 to 10 carbon atoms, and processes for the preparation thereof, and a pharmaceutical composition containing as an active ingredient the compound (I), which is particularly suitable for the prophylaxis and treatment of circulatory diseases.
Prior Art
A plenty of investigation have hitherto been done as to 1,4-dihydropyridine derivatives, particularly their 3,5-dicarboxylic acid esters, and some compounds are known to exhibit interesting coronary vasodilatory activity and hypotensive activity. For example, nifedipine [chemical name: dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitophenyl)3,5-pyridinedicarboxylate] (Compound A) is widely used as a medicine for the prophylaxis and treatment of angina pectoris, and nicardipine [chemical name: methyl, N-benzyl-N-methylaminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate hydrochloride] (Compound B) is widely used as a hypotensive or cerebral vasodiltory agent. Moreover, some 1,4-dihydropyridine-3,5-asymetic dicarboxylic acid esters are disclosed in Japanese Patent Second Publication (Kokoku) No. 29989/1980 and Japanese Patent First Publication (Kokai) Nos. 146565/1983 and 7255/1986.
Besides, there are known some compounds analogous to the compounds of this invention, for example, 3-aminocarbonyl-1,4-dihydropyridiene-5-carboxylic acid compounds in German Patent First Publication (Offenlegungsschrift) No. 2,228,377, Japanese Patent Second Publication (Kokoku) No. 20953/1982, and Japanese Patent First Publication (Kokai) No. 116267/1984, and 1,4-dihydropyridine-3-nitro-5-carboxylic cycloalkylamide in Japanese Patent First Publication (Kokai) No 227860/1984. Among theses, the following compounds have a chemical structure most similar to that of the compounds of this invention. ##STR3##
These compounds are different from the compounds of this invention in the amido substituent and alkyl ester groups, and these literatures disclose insufficiently the pharmacological activities thereof.
BRIEF SUMMARY OF THE INVENTION
An object of the invention is to provide novel 3-aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds of the formula [I] which have excellent pharmacological activities. Another object of the invention is to provide novel compounds [I] as set forth above which are suitable for prophylaxis and treatment of circulator diseases, particularly hypertension and angina pectoris. A further object of the invention is to provide processes for preparing these compounds. Still further object of the invention is to provide a pharmaceutical composition containing as an active ingredient the compound [I]. These and other objects and advantages of the invention will be apparent to skilled persons from the following description.
DETAILED DESCRIPTION OF THE INVENTION
The novel 3-aminocarbonyl-1,4-dihydropyridine-5carboxylic acid compounds of the invention have the formula [I] as disclosed hereinbefore.
The alkyl for R.sup.1 in the formula [I] denotes a straight or branched chain alkyl group having 1 to 5 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, etc., preferably an alkyl having 3 to 5 carbon atoms, particularly preferably isopropyl. The alkenyl for R.sup.1 denotes an alkenyl group having 2 to 5 carbon atoms, such as vinyl, allyl, 2-butenyl, 2-pentenyl, etc., particularly preferably allyl. The alkynyl denotes an alkynyl group having 3 to 5 carbon atoms, such as propargyl, 2-butyn-1-yl, etc., particularly preferably propargyl. The alkyl for R.sup.2 denotes a straight or branched chain alkyl group having 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, 3-methyl-2-butyl, n-pentyl, isopentyl, 2-pentyl, 3-pentyl, tert-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, etc., preferably an alkyl having 1 to 9 carbon atoms, more preferably an alkyl having 1 to 3 or 6 to 9 carbon atoms, particularly preferably n-hexyl, n-heptyl, n-octyl, and n-nonyl. The NO.sub.2 group is substituted at ortho (o) or meta (m) position, preferably o-position.
The compounds of this invention can be prepared by various processes, for example by the following processes. ##STR4## wherein the substitution position of NO.sub.2, R.sup.1 and R.sup.2 are as defined above.
As is shown in the above Reaction Scheme-1, an alkyl o-(or m-)nitrobenzylideneacetoacetate [II] and a 3aminocrotonamide [III] are subjected to a cyclization reaction in an appropriate solvent to give the desired compound [I].
This reaction is usually carried out at a temperature of from room temperature to about 160.degree. C., preferably about 50.degree. to 130.degree. C., more particularly at a boiling temperature of an appropriate inert solvent. The solvent includes, for example, aromatic hydrocarbons (e.g. benzene, toluene, xylene), alcohols (e.g. methanol, ethanol, propanol, isopropanyl, n-butanol, sec-butanol, etc.), ethers (e.g. diethyl ether, dioxane, tetrahydrofuran, ethylene glycol monomethyl ether, ethylene glycol dimethyl ether, etc.), acetic acid, pyridine, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, and the like. The reaction is preferably carried out while removing the produced water by azeotropic distillation using a non-polar solvent (e.g. benzene, toluene, xylene, etc.). In this case, the reaction is completed when a stoichiometic amount of water is distilled out. By this process, the desired compound [I] can be obtained in higher yield with less by-product in comparison with a process using other solvent.
The above reaction is usually completed in a period of 1 to 7 hours. The amount of the starting compounds is in the range of [II]:[III]=1:1.5 mole to 1.5:1 mole.
The starting compound [II] is known or can be prepared by a known process as shown in the following Reaction Scheme-2 [cf. Organic Reactions, 15, 204-599 (1967)]. ##STR5## wherein the substitution position of NO.sub.2 group and R.sup.2 are as defined above.
That is, a nitrobenzaldehyde [IV] is reacted with an alkyl acetoacetate [V] in an appropriate solvent to give the compound [II]. This reaction can be carried out under the conditions similar to those in Reaction Scheme-1 by using similar solvent. The compound [II] may be used for the reaction with the compound [III] in the Reaction Scheme-1 after isolation from the reaction mixture or without isolation. The reactions of Reaction Schemes-1 and -2 may continuously be carried out in a single reaction system. That is, when the nitrobenzaldehyde [IV], alkyl acetoacetate [V] and 3-aminocrotonamide [III] are reacted under the same conditions as in Reaction Scheme-1, the desired compound [I] can directly be obtained. In this case, the starting compounds are used in the ratio of [IV]:[V]:[III]=1-1.5 mole:1-1.5 mole:1-1.5 mole.
The starting nitrobenzaldehyde [IV] used in Reaction Scheme-2 is known and the other starting alkyl acetoacetate [V] is also known or can be prepared by a known process, for example, by the process as shown in the following Reaction Scheme-3 (cf. U.S. Pat. No. 2,351,366). ##STR6## wherein R.sup.2 is as defined above.
That is, a diketene [VI] is reacted with an alcohol [VII] in the presence of a basic catalyst in an inert solvent or without using any solvent at a temperature of about 40.degree. to 130.degree. C. to give the desired compound [V].
The other starting 3-aminocrotonamide [III] used in the above Reaction Scheme-1 is also known or can be prepared by a known process as shown in the following Reaction Scheme-4 [cf. J. Am. Chem. Soc., 67, 1017 (1945)]. ##STR7## wherein R.sup.1 is as defined above.
That is, an acetoacetamide [VIII] is dissolved in an appropriate solvent (e.g. methanol, ethanol, diethyl ether, dioxane, tetrahydrofuran, etc.) and thereto is blown an excess amount of ammonia gas at about 0.degree. to 60.degree. C. or is added a solution of ammonia in the above mentioned solvent, and the mixture is reacted in a sealed reactor at about 0.degree. to 60.degree. C. to give the desired compound [III]. ##STR8## wherein the substitution position of NO.sub.2, R.sup.1 and R.sup.2 are as defined above.
The compounds [I] of this invention can also be prepared by the process as shown in the above Reaction Scheme-5. That is, an o-(or m-)nitrobenzylideneacetoacetamide [IX] and an alkyl 3-aminocrotonate [X] are subjected to cyclization reaction in an appropriate solvent to give the desired compound [I]. This reaction can be done under substantially the same conditions as those in Reaction Scheme-1.
The starting compound [IX] is known or can be prepared by a known process as shown in the following Reaction Scheme-6 [Organic Reactions, 15, 204-599 (1967)]. ##STR9## wherein the substitution position of NO.sub.2 and R.sup.1 are as defined above.
That is, a nitrobenzaldehyde [IV] is reacted with an acetoacetamide [VIII] in an appropriate solvent to give the compound [IX]. This reaction can be carried out under the same conditions using the same solvent as those in the above Reaction Scheme-5. The product [IX] obtained in this reaction can be used to the reaction with the compound [X] in the above Reaction Scheme-5 after being isolated from the reaction mixture or without isolation. Thus, the reactions of Reaction Scheme-5 and Reaction Scheme-6 may continuously be carried out in a single reaction system. That is, when the nitrobenzaldehyde [IV], alkyl acetoacetamide [VIII] and alkyl 3-aminocrotonate [X] are reacted under the same conditions as in Reaction Scheme-5, the desired compound [I] can directly be obtained. In this case, the starting compounds are used in the ratio of [IV]:[VIII]:[X]=1-1.5 mole:1-1.5 mole:1-1.5 mole.
The starting acetoacetamide [VIII] used in Reaction Scheme-6 is also known or can be prepared by a known process, for example, by the process as shown in the following Reaction Scheme-7 (cf. German Pat. No. 1,142,859). ##STR10## wherein R.sup.1 is as defined above.
That is, a diketene [VI] is reacted with an amine [XI] in an inert solvent at a temperature of about -10.degree. to 30.degree. C. to give the desired compound [VIII].
The other starting alkyl 3-aminocrotonate [X] used in the above Reaction Scheme-5 is also known or can be prepared by a known process as shown in the following Reaction Scheme-8 [cf. J. Am. Chem. Soc., 67, 1017 (1945)]. ##STR11## wherein R.sup.2 is as defined above.
The reaction can be carried out under substantially the same conditions as those in the process of Reaction Scheme-4.
The compounds [I] obtained by the above processes can be isolated and purified from the reaction mixture by conventional isolation and purification methods, such as concentration, extraction, chromatography, re-precipitation, recrystallization, and the like.
The compounds of this invention have excellent pharmacological activities, for example, hypotensive, peripheral vasodilatory, coronary vasodilatory, cerebral vasodilatory and kidney vasodilatory activities, which activities are exhibited in mild with long lasting. Particularly, in comparison with the known 1,4-dihydropyridine derivatives (e.g. nifedipine, nicardipine hydrochloride), higher activities are exhibited in more mild with longer lasting. In view of the excellent properties which are not shown by the known compounds, the compounds of this invention are particularly useful. For instance, in case of the prophylaxis and treatment of hypertension, the compounds of this invention can exhibit stable hypotensive activity with less administration times (e.g. once or twice per day). Accordingly, the compounds of this invention are useful, for example, for the prophylaxis and treatment of hypertension, ischemic heart diseases (e.g. angina pectoris, myocardial infarction, etc.), and cerebral and peripheral circulation diseases.
The compounds of this invention can be used as a medicament in the form of a conventional pharmaceutical preparation in admixture with conventional pharmaceutically acceptable carriers, excipients and diluents. The pharmaceutical preparations include solid preparations such as powders, granules, fine granules, tablets, capsules, suppositories, and liquid preprations such as solutions, suspensions, emulsions, injections, and the like. These preparations are administered in oral route or in parenteral route. The dose of the compounds of this invention may vary according to the administration routes, severity of the disease, the sex, age and weight of the patient, but is usually in the range of 0.5 to 500 mg/day, preferably 1.0 to 150 mg/day, in case of adult patient suffering from hypertension, which may be divided one to several times per day.
The present invention is illustrated by the following Preparations, Examples and Experiments. In the Preparations and Examples, the melting point (no correction) of the compounds is measured by a heat plate method (using MP-S 2 type heat plate, manufactured by Yanagimoto, Japan).
Preparation 1
Preparation of methyl o-nitrobenzylideneacetoacetate:
o-Nitrobenzaldehyde (7.6 g, 0.05 mole) and methyl acetoacetate (5.8 g, 0.05 mole) are dissolved in benzene (40 ml), and thereto are added piperidine (0.2 ml) and acetic acid (0.6 ml), and the mixture is refluxed for 5 hours. The produced water is removed, and when a stoichiometic amount of water is distilled off, the reaction is stopped. After completion of the reaction, the reaction mixture is washed with 5% hydrochloric acid and then with water, and the solvent is distilled off under reduced pressure to give the title compound (12.2 g, yield 98%) as a brown oil.
Preparation 2
Preparation of 3-aminocrotonic methylamide:
N-methyl-acetoacetamide (175.4 g, 1.58 mole) is dissolved in ethanol (55 ml) and thereto is passed ammonia gas, wherein the temperature is controlled below 30.degree. C. by cooling with water bath. After passing ammonia gas for about 3 hours, yellow crystals are precipitated. The mixture is allowed to stand at 0.degree. C. for overnight. The resulting precipitates are washed with diethyl ether to give the title compound (115.2 g, yield 66%) as colorless prisms, m.p. 102.degree. to 107.degree. C.
In the same manner as described above, various compounds as shown in Table 1 are prepared.
TABLE 1______________________________________ ##STR12##Prepr. Melting point YieldNo. R.sup.1 (.degree.C.) (%)______________________________________3 H 99-100 94.34 C.sub.2 H.sub.5 130-135 74.95 n-C.sub.3 H.sub.7 120-124 62.76 iso-C.sub.3 H.sub.7 143-145 54.67 n-C.sub.4 H.sub.9 Semi-solid 91.28 iso-C.sub.4 H.sub.9 Oil 98.09 sec-C.sub.4 H.sub.9 Semi-solid 73.010 tert-C.sub.4 H.sub.9 Oil 98.011 n-C.sub.5 H.sub.11 Oil 88.612 iso-C.sub.5 H.sub.11 Oil 87.5______________________________________
Preparation 13
Preparation of o-nitrobenzylideneacetoacetic isopropylamide:
o-Nitrobenzaldehyde (43.4 g, 0.29 mole) and acetoacetic isopropylamide (40.0 g, 0.29 mole) are dissolved in benzene (150 ml) and thereto are added piperidine (1.15 ml) and acetic acid (3.45 ml), and the mixture is refluxed and the produced water is removed. After the stoichiometic amount of water is distilled off, the reaction is stopped. After the reaction, the solvent is distilled off under reduced pressure, and the residue is recrystallized from ethanol to give the title compound (62.7 g, yield 78.4%) as colorless prisms, m.p. 132.degree.-135.degree. C.
IR (KBr, cm.sup.-1): 1690, 1630, 1510, 1340
NMR (CDCl.sub.3, .delta.: ppm): 0.91 (6H, d), 2.44 (3H, s), 3.60-4.20 (1H, m), 5.90-6.45 (1H, bd.), 7.15-8.25 (4H, m), 7.78 (1H, s)
Elementary analysis for Cl.sub.4 H.sub.16 N.sub.2 O.sub.4 : Calcd. (%): C,60.86: H,5.84: N,10.14 Found (%): C,60.64: H,5.89; N,10.01
Preparation 14
Preparation of 3-aminocrotonic allylamide:
Acetoacetic allylamide (111.4 g, 0.79 mole) is dissolved in ethanol (80 ml) and thereto is passed ammonia gas, while the temperature is controlled below 30.degree. C. by cooling with a water bath. After passing ammonia gas for about 3 hours, colorless crystals precipitate. The reaction mixture is allowed to stand at 0.degree. C. overnight. The precipitates are separated by filtration and washed with diethyl ether to give the title compound (91.5 g, yield 82.7%) as colorless prisms, m.p. 143.degree.-144.degree. C.
Elementary analysis for C.sub.7 H.sub.12 N.sub.2 O: Calcd. (%): C,59.97: H,8.63: N,19.99 Found (%): C,59.78: H,8.76; N,20.08
Preparation 15
Preparation of 3-aminocrotonic propargylamide:
Acetoacetic propargylamide (93.4 g, 0.67 mole) is dissolved in ethanol (70 ml) and thereto is passed ammonia gas, while the temperature is controlled below 30.degree. C. by cooling with a water bath. After passing ammonia gas for about 3 hours, colorless crystals precipitate. The reaction mixture is allowed to stand at 0.degree. C. overnight. The precipitates are separated by filtration and washed with diethyl ether to give the title compound (87.7 g, yield 94.6%) as colorless needles, m.p. 137.degree.-138.degree. C.
Elementary analysis for C.sub.7 H.sub.10 N.sub.2 O: Calcd. (%): C,60.85: H,7.30; N,20.28 Found (%): C,60.80; H,7.34: N,20.56
Preparation 16
Preparation of o-nitrobenzylideneacetoacetic allylamide:
o-Nitrobenzaldehyde (7.6 g, 0.05 mole) and acetoacetic allylamide (7.1 g, 0.05 mole) are dissolved in benzene (40 ml) and thereto are added piperidine (0.2 ml) and acetic acid (0.6 ml), and the mixture is refluxed for 2 hours and the produced water is removed. After the stoichiometic amount of water is distilled off, the reaction is stopped. After the reaction, the reaction mixture is washed with 5% hydrochloric acid and then with water, and the solvent is distilled off under reduced pressure, and to the residue is added diethyl ether, and the obtained crude crystals are recrystallized from ethanol to give the title compound (9.6 g, yield 69.7%) as colorless needles, m.p. 128.degree.-129.degree. C.
Elementary analysis for C.sub.14 H.sub.14 N.sub.2 O.sub.4 : Calcd. (%): C,61.31; H,5.15; N,10.21 Found (%): C,61.38: H,5.13: N,10.10
Preparation 17
Preparation of o-nitrobenzylideneacetoacetic propargylamide:
o-Nitrobenzaldehyde (7.6 g, 0.05 mole) and acetoacetic propargylamide (7.0 g, 0.05 mole) are dissolved in benzene (40 ml) and thereto are added piperidine (0.2 ml) and acetic acid (0.6 ml), and the mixture is refluxed for 2 hours and the produced water is removed. After the stoichiometic amount of water is distilled off, the reaction is stopped. After the reaction, the reaction mixture is washed with 5% hydrochloric acid and then with water, and the solvent is distilled off under reduced pressure, and to the residue is added diethyl ether, and the obtained crude crystals are recrystallized from ethanol to give the title compound (10.9 g, yield 80.2%) as colorless needles, m.p. 136.degree.-137.degree. C.
Elementary analysis for C.sub.14 H.sub.12 N.sub.2 O.sub.4 : Calcd. (%): C,61.76: H,4.44: N,10.29 Found (%): C,61.64; H,4.43: N,10.26
Preparation of 18
Preparation of acetoacetic cyclopropylamide:
Cyclopropylamine (42.2 g, 0.74 mole) is dissolved in chloroform (300 ml) and thereto is added dropwise diketene (62.1 g, 0.74 mole) over a period of 1-1.5 hour with stirring in an ice bath. After the addition, the mixture is stirred at 40.degree. C. for one hour, and the solvent is distilled off under reduced pressure, and the residue is recrystallized from benzene-n-hexane to give the title compound (83.4 g, yield 80%) as colorless needles, m.p. 65.degree.-66.degree. C.
Elementary analysis for C.sub.7 H.sub.11 NO.sub.2 Calcd. (%): C,59.55: H,7.85: N,9.92 Found (%): C,59.37: H,7.99; N,9.68
Preparation 19
Preparation of 3-aminocrotonic cyclopropylamide:
Acetoacetic cyclopropylamide (209.4 g, 1.48 mole) is dissolved in ethanol (160 ml) and thereto is passed ammonia gas, while the temperature is controlled below 30.degree. C. by cooling with a water bath. After passing ammonia gas for about 3 hours, yellow crystals precipitate. The reaction mixture is allowed to stand at 0.degree. C. overnight. The precipitates are separated by filtration and washed with diethyl
(172.2 g, yield 82.8%) as colorless prisms, m.p. 169.degree.-171.degree. C.
Elementary analysis for C.sub.7 H.sub.12 N.sub.2 O: Calcd. (%): C,59.97: H,8.63: N,19.99 Found (%): C,59.71: H,8.77: N,20.17
Preparation 20
Preparation of 3-aminocrotonic cyclopentylamide:
Acetoacetic cyclopentylamide (169.1 g, 1.00 mole) is dissolved in ethanol (100 ml) and thereto is passed ammonia gas, while the temperature is controlled below 30.degree. C. by cooling with a water bath. After passing ammonia gas for about 3 hours, colorless crystals precipitate. The reaction mixture is allowed to stand at 0.degree. C. overnight. The precipitates are separated by filtration and washed with diethyl ether to give the title compound (140.4 g, yield 85.6%) as colorless needles, m.p. 138.degree.-139.degree. C.
Elementary analysis for C.sub.9 H.sub.16 N N.sub.2 O: Calcd. (%): C,64.25: H,9.59: N,16.65 Found (%): C,64.03: H,9.79; N,16.53
Preparation 21
Preparation of o-nitrobenzylideneacetoacetic cyclopropylamide:
o-Nitrobenzaldehyde (7.6 g, 0.05 mole) and acetoacetic cyclopropylamide (7.1 g, 0.05 mole) are dissolved in benzene (40 ml) and thereto are added piperidine (0.2 ml) and acetic acid (0.6 ml), and the mixture is refluxed for 2 hours and the produced water is removed. After the stoichiometic amount of water is distilled off, the reaction is stopped. After the reaction, the reaction mixture is washed with 5% hydrochloric acid and then with water, and the solvent is distilled off under reduced pressure, and to the residue is added diethyl ether, and the obtained crude crystals are recrystallized from ethanol to give the title compound (10.4 g, yield 75.6%) as colorless needles, m.p. 133.degree.-134.degree. C.
Elementary analysis for C.sub.14 H.sub.14 N.sub.2 O.sub.4 : Calcd. (%): C,61.31: H,5.15: N,10.21 Found (%): C,61.55: H,5.20: N,10.12
Preparation 22
Preparation of o-nitrobenzylideneacetoacetric cyclopentylamide:
o-Nitrobenzaldehyde (7.6 g, 0.05 mole) and acetoacetic cyclopentylamide (8.5 g, 0.05 mole) are dissolved in benzene (40 ml) and thereto are added piperidine (0.2 ml) and acetic acid (0.6 ml), and the mixture is refluxed for 2 hours and the produced water is removed. After the stoichiometic amount of water is distilled off, the reaction is stopped. After the reaction, the reaction mixture is washed with 5% hydrochloric acid and then with water, and the solvent is distilled off under reduced pressure, and to the residue is added diethyl ether, and the obtained crude crystals are recrystallized from ethanol to give the title compound (10.6 g, yield 70.2%) as colorless prisms, m.p. 132.degree.-134.degree. C.
Elementary analysis for C.sub.16 H.sub.18 N.sub.2 O.sub.4 : Calcd. (%): C,63.56: H,6.00; N,9.27 Found (%): C,63.40; H,6.13: N,9.35





EXAMPLE 1
Preparation of n-heptyl 2,6-dimethyl-3-isopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Heptyl o-nitrobenzylideneacetoacetate (16.7 g, 0.05 mole) and 3-aminocrotonic isopropylamide (7.1 g, 0.05 mole) are dissolved in benzene (100 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (15.7 g, yield 68.6%) as yellow prisms, m.p. 137.degree.-139.degree. C.
IR (KBr, cm.sup.-1): 1680, 1525, 1355
NMR (DMSO, .delta.: ppm): 0.70-1.30 (13H, m), 0.85-1.10 (6H, d.d), 2.00 (3H, s), 2.20 (3H, s), 3.50-4.00 (3H, m), 5.25 (1H, s), 7.00-7.65 (4H, m), 7.08 (1H, d), 8.20 (1H, s)
Elementary analysis for C.sub.25 H.sub.35 N.sub.3 O.sub.5 : Calcd. (%): C,65.62; H,7.71: N,9.18 Found (%): C,65.90: H,7.67: N,9.46
EXAMPLE 2
Preparation of n-octyl 2,6-dimethyl-3-isopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Octyl o-nitrobenzylideneacetoacetate (17.4 g, 0.05 mole) and 3-aminocrotonic isopropylamide (7.1 g, 0.05 mole) are dissolved in benzene (100 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (13.8 g, yield 58.4%) as yellow prisms, m.p. 126.degree.-129.degree. C.
IR (KBr, cm.sup.-1): 1685, 1525, 1355
NMR (DMSO, .delta.: ppm): 0.80-1.50 (15H, m), 0.85-1.10 (6H, d.d), 2.00 (3H, s), 2.20 (3H, s), 3.50-4.00 (3H, m), 5.25 (1H, s), 7.00-7.65 (4H, m), 7.10 (1H, d), 8.25 (1H, s)
Elementary analysis for C.sub.26 H.sub.37 N.sub.3 O.sub.5 : Calcd. (%): C,66.22: H,7.91: N,8.91 Found (%): C,66.15: H,7.80: N,8.82
EXAMPLE 3
Preparation of n-nonyl 2,6-dimethyl-3-isopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Nonyl o-nitrobenzylideneacetoacetate (18.1 g, 0.05 mole) and 3-aminocrotonic isopropylamide (7.1 g, 0.05 mole) are dissolved in benzene (100 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.6 g, yield 60.3%) as yellow prisms, m.p. 147.degree.-149.degree. C.
IR (KBr, cm.sup.-1): 1685, 1525, 1355
NMR (DMSO, .delta.: ppm): 0.80-1.50 (17H, m), 0.85-1.10 (6H, d.d), 2.00 (3H, s), 2.20 (3H, s), 3.50-4.00 (3H, m), 5.30 (1H, s), 7.00-7.65 (4H, m), 7.14 (1H, d), 8.25 (1H, s)
Elementary analysis for C.sub.27 H.sub.95 N.sub.3 O.sub.5 : Calcd. (%): C,66.78: H,8.10: N,8.65 Found (%): C,66.73: H,7.97: N,8.48
EXAMPLE 4
Preparation of n-hexyl 2,6-dimethyl-3-aminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5carboxylate:
n-Hexyl o-nitrobenzylideneacetoacetate (16.0 g, 0.05 mole) and 3-aminocrotonamide (5.0 g, 0.05 mole) are dissolved in ethanol (100 ml), and the mixture is refluxed for 8 hours. After the reaction, the solvent is distilled off under reduced pressure. The residue is dissolved in eluting solvent [chloroform:carbon tetrachloride:ethyl formate:formic acid:ethanol (10:10:8:1:2)] (30 ml) and subjected to column chromatography [silica gel 60 Art. 9385 (Manufactured by Merck Co.), 600 g, .phi.40 mm.times.1 m]. The fraction containing the desired compound is regulated to pH 10 with 28% aqueous ammonia, and the organic layer is separated, washed with water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue is recrystallized from ethanol to give the title compound (17.1 g, yield 80.6%) as yellow prisms, m.p. 120.degree.-123.degree. C.
IR (KBr, cm.sup.-1): 1680, 1520, 1350
NMR (DMSO, .delta.: ppm): 0.50-1.50 (11H, m), 2.10 (3H, s), 2.20 (3H, s), 3.50-4.00 (3H, m), 5.32 (1H, s), 6.75 (2H, s), 7.00-7.70 (4H, m), 8.35 (1H, s)
Elementary analysis for C.sub.21 H.sub.27 N.sub.3 O.sub.5 .multidot.1/2C.sub.2 H.sub.5 OH: Calcd. (%): C,62.25; H,7.12: N,9.90 Found (%): C,62.36; H,7.14: N,9.98
EXAMPLE 5
Preparation of methyl 2,6-dimethyl-3-isopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
o-Nitrobenzylideneacetoacetic isopropylamide (4.5 g, 0.016 mole) and methyl 3-aminocrotonate (2.0 g, 0.016 mole) are dissolved in ethanol (10 ml), and the mixture is refluxed for 14 hours. After the reaction, the solvent is distilled off under reduced pressure. The residue is dissolved in elution solvent [chloroform:carbon tetrachloride:ethyl formate:formic acid:ethanol (10:10:8:1:2)] (30 ml) and subjected to column chromatography [silica gel 60 Art. 9385 (Manufactured by Merck Co.), 300 g, .phi.40 mm.times.50 cm]. The fraction containing the desired compound is regulated to pH 10 with 28% aqueous ammonia, and the organic layer is separated, washed with water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue is recrystallized from ethanol to give the title compound (3.6 g, yield 57.0%) as yellow prisms, m.p. 203.degree.-206.degree. C.
IR (KBr, cm.sup.-1): 1680, 1525, 1360
NMR (DMSO, ppm): 0.90-1.20 (6H, d.d), 2.10 (3H,
(3H, s), 3.45 (3H, s), 3.60-4.10 (1H, m), 5.32 (1H, s), 7.30-7.90 (5H, m), 8.55 (1H, s)
Elementary analysis for C.sub.19 H.sub.23 N.sub.3 O.sub.5 : Calcd. (%): C,61.11: H,6.21: N,11.25 Found (%): C,60.84; H,5.99; N,11.32
EXAMPLE 6
Preparation of n-butyl 2,6-dimethyl-3-isopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
o-nitrobenzylideneacetoacetic isopropylamide (13.8 g, 0.05 mole) and n-butyl 3-aminocrotonate (7.9 g, 0.05 mole) are dissolved in benzene (100 ml), and the mixture is refluxed for 5 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (8.3 g, yield 40.0%) as yellow prisms, m.p. 194.degree.-196.degree. C.
IR (KBr, cm.sup.-1): 1675, 1525, 1355
NMR (DMSO, .delta.: ppm): 0.70-1.20 (6H, m), 0.70-1.70 (7H, m), 2.10 (3H, s), 2.30 (3H, s), 3.50-4.10 (3H, m), 5.50 (1H, s), 7.30-7.95 (4H, m), 7.42 (1H, d), 8.55 (1H, s)
Elementary analysis for C.sub.22 H.sub.29 N.sub.3 O.sub.5 : Calcd. (%): C,63.59: H,7.04: N,10.11 Found (%): C,63.76: H,6.82: N, 9.84
EXAMPLE 7
Preparation of n-hexyl 2,6-dimethyl-3-isopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
o-Nitrobenzaldehyde (3.8 g, 0.025 mole), n-hexyl acetoacetate (4.6 g, 0.025 mole) and 3-aminocrotonic isopropylamide (3.5 g, 0.025 mole) are dissolved in ethanol (50 ml), and the mixture is refluxed for 8 hours. After the reaction, the solvent is distilled off under reduced pressure. The residue is dissolved in elution solvent [chloroform:carbon tetrachloride:ethyl formate:formic acid:ethanol (10:10:8:1:2)] (30 ml) and subjected to column chromatography [silica gel 60 Art. 9385 (Manufactured by Merck Co.), 300 g, .phi.40 mm.times.50 cm]. The fraction containing the desired compound is regulated to pH 10 with 28% aqueous ammonia, and the organic layer is separated, washed with water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue is recrystallized from 80% ethanol to give the title compound (3.31 g, yield 29.9%) as yellow prisms, m.p. 175.degree.-178.degree. C.
IR (KBr, cm.sup.-1): 1675, 1525, 1360
NMR (DMSO, .delta.: ppm): 0.60-1.60 (9H, m), 0.80-1.10 (6H, d.d), 2.00 (3H, s), 2.20 (3H, s), 3.50-4.00 (3H, m), 5.30 (1H, s), 7.00-7.70 (4H, m), 7.15 (1H, d), 8.25 (1H, s)
Elementary analysis for C.sub.24 H.sub.33 N.sub.3 O.sub.5 : Calcd. (%): C,64.99: H,7.50: N,9.47 Found (%): C,65.20; H,7.59: N,9.47
EXAMPLE 8
Preparation of n-pentyl 2,6-dimethyl-3-isopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
o-Nitrobenzaldehyde (3.8 g, 0.025 mole), n-pentyl 3-aminocrotonate (4.3 g, 0.025 mole) and acetoacetic isopropylamide (3.6 g, 0.025 mole) are dissolved in ethanol (50 ml), and the mixture is refluxed for 8 hours. After the reaction, the solvent is distilled off under reduced pressure. The residue is dissolved in elution solvent [chloroform:carbon tetrachloride:ethyl formate:formic acid:ethanol (10:10:8:1:2)] (30 ml) and subjected to column chromatography [silica gel 60 Art. 9385 (Manufactured by Merck Co.), 300 g, .phi.40 mm.times.50 cm]. The fraction containing the desired compound is regulated to pH 10 with 28% aqueous ammonia, and the organic layer is separated, washed with water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue is recrystallized from 80% ethanol to give the title compound (3.2 g, yield 30.0%) as yellow prisms, m.p. 186.degree.-189.degree. C.
IR (KBr, cm.sup.-1): 1680, 1525, 1360
NMR DMSO, .delta.: ppm): 0.60-1.20 (6H, m), 0.60-1.60 (9H, m), 2.00 (3H, s), 2.20 (3H, s), 3.50-4.00 (3H, m), 5.30 (1H, s), 7.00-7.70 (4H, m), 7.17 (1H, d), 8.30 (1H, s)
Elementary analysis for C.sub.23 H.sub.31 N.sub.3 O.sub.5 : Calcd. (%): C,64.31; H,7.28; N,9.78 Found (%): C,64.45; H,7.34; N,10.04
EXAMPLES 9 TO 70
In the same manner as described in Examples 1 to 8, the compounds are shown in Table 2 are prepared, wherein the compounds obtained in Examples 9 to 56 has the NO.sub.2 group at ortho-position, and the compounds obtained in Examples 57 to has the NO.sub.2 group at meta-position.
TABLE 2__________________________________________________________________________ AppearanceEx. M.p. (solvent for re-No. R.sup.1 R.sup.2 (.degree.C.) crystallization)__________________________________________________________________________9 H C.sub.2 H.sub.5 209-211 Yellow prisms (ethanol)10 " C.sub.3 H.sub.7 (n) 178-180 "11 " C.sub.3 H.sub.7 (iso) 219-221 "12 " C.sub.4 H.sub.9 (n) 100-103 Yellow prisms (ethyl acetate)13 " C.sub.4 H.sub.9 (iso) 194-196 "14 " C.sub.4 H.sub.9 (sec) 180-182 "15 " C.sub.4 H.sub.9 (tert) 232-234 Yellow prisms (ethanol)16 " C.sub.5 H.sub.11 (n) 112-115 "17 " C.sub.5 H.sub.11 (iso) 163-165.5 Yellow prisms (ethyl acetate)18 " ##STR13## 181-183 Yellow prisms (ethanol)19 H C.sub.5 H.sub.11 (sec) 152-154 Yellow prisms (ethyl acetate)20 " C.sub.5 H.sub.11 (tert) 187-189 Yellow prisms (ethanol)21 " ##STR14## 172-174 Yellow prisms (ethyl acetate)22 " C.sub.7 H.sub.15 (n) 120-124 Yellow prisms (ethanol)23 " C.sub.8 H.sub.17 (n) 187-189 "24 CH.sub.3 C.sub.2 H.sub.5 203-205 "25 " C.sub.3 H.sub.7 (n) 203-204 "26 " C.sub.4 H.sub.9 (n) 188-190 Pale Yellow prisms (ethanol)27 " C.sub.5 H.sub.11 (iso) 212-214 Yellow prisms (ethanol)28 " C.sub.6 H.sub.13 (n) 119-122 Yellow prisms (ethyl acetate)29 C.sub.2 H.sub.5 C.sub.2 H.sub.5 182-185 Yellow prisms (ethanol)30 " C.sub.3 H.sub.7 (n) 188-191 "31 " C.sub.4 H.sub.9 (n) 171-173 "32 " C.sub.5 H.sub.11 (n) 169-171 Yellow prisms (ethanol + H.sub.2 O)33 " C.sub.5 H.sub.11 (iso) 154-157 Yellow prisms (ethanol)34 C.sub.2 H.sub.5 C.sub.7 H.sub.15 (n) 86-88 Yellow prisms [ethanol + iso-(C.sub.3 H.sub.7).sub.2 O]35 C.sub.3 H.sub.7 (n) CH.sub.3 195-197 Yellow prisms (ethanol)36 " C.sub.2 H.sub.5 154-156 Orange prisms (ethanol)37 " C.sub.3 H.sub.7 (n) 150-152 Pale yellow prisms (ethanol)38 " C.sub.4 H.sub.9 (n) 142-144 Yellow prisms (ethanol)39 " C.sub.5 H.sub.11 (n) 156-158 Yellow prisms (ethanol + H.sub.2 O)40 " C.sub.5 H.sub. 11 (iso) 170-172 Yellow prisms (ethanol)41 "C.sub.6 H.sub.13 (n) 157-160 Yellow prisms (dil. ethanol)42 " C.sub.7 H.sub.15 (n) 130-132 "43 C.sub.3 H.sub.7 (iso) C.sub.2 H.sub.5 216-218 Yellow prisms (ethanol)44 " C.sub.3 H.sub.7 (n) 150-152 "45 " C.sub.3 H.sub.7 (iso) 182-185 "46 " C.sub.4 H.sub.9 (iso) 196-199 "47 " C.sub.5 H.sub.11 (iso) 197-199 Pale yellow prisms (ethanol)48 " ##STR15## 175-178 Yellow prisms (dil. ethanol)49 C.sub.3 H.sub.7 (iso) C.sub.5 H.sub.11 (sec) 180-182 Orange prisms (dil. ethanol)50 " ##STR16## 205-208 Yellow prisms (dil. ethanol)51 " C.sub.6 H.sub.13 (iso) 175-177 "52 " C.sub.10 H.sub.21 (n) 126-129 "53 C.sub.4 H.sub.9 (n) C.sub.5 H.sub.11 (iso) 152-158 "54 C.sub.4 H.sub.9 (iso) C.sub.5 H.sub.11 (iso) 175-17855 C.sub.5 H.sub.11 (n) " 130-132 "56 C.sub.5 H.sub.11 (iso) " 166-169 "57 H C.sub.3 H.sub.7 (iso) 188-190 Yellow prisms (ethanol)58 " C.sub.4 H.sub.9 (tert) 178.5-179 Yellow prisms (benzene + n-hexane)59 C.sub.2 H.sub.5 C.sub.4 H.sub.9 (n) 185-187 Yellow prisms (ethanol + H.sub.2 O)60 C.sub.3 H.sub.7 (iso) CH.sub.3 180-181 "61 " C.sub.2 H.sub.5 193-195 Pale yellow prisms (ethanol + H.sub.2 O)62 " C.sub.3 H.sub.7 (n) 213-214 Yellow prisms (ethanol)63 " C.sub.3 H.sub.7 (iso) 193-194 Yellow prisms (methanol)64 C.sub.3 H.sub.7 (iso) C.sub.4 H.sub.9 (n) 200-202 Yellow prisms (ethanol + H.sub.2 O)65 " C.sub.4 H.sub.9 (iso) 238-241 Yellow prisms (Tetrahydrofuran + methanol)66 " C.sub.5 H.sub.11 (n) 190-193 Yellow prisms (ethanol)67 " C.sub.5 H.sub.11 (iso) 198-201 "68 C.sub.3 H.sub.7 (n) C.sub.4 H.sub.9 (n) 155-157 Yellow prisms (ethanol + H.sub.2 O)69 C.sub.4 H.sub.9 (n) C.sub.4 H.sub.9 (n) 132-134 "70 C.sub.4 H.sub.9 (iso) " 155-157 "__________________________________________________________________________
EXAMPLE 71
Preparation of methyl 2,6-dimethyl-3-allylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydrophridine-5-carboxylate:
Methyl o-nitrobenzylideneacetoacetate (12.5 g, 0.05 mole) and 3-aminocrotonic allylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (15.7 g, yield 84.3%) as yellow prisms, m.p. 175.degree.-177.degree. C.
IR (KBr, cm.sup.-1): 1680, 1525, 1355
NMR (DMSO, .delta.: ppm): 2.08 (3H, s), 2.20 (3H, s), 3.35 (3H, s), 3.50-3.85 (2H, m), 4.65-4.90 (1H, m), 5.00 (1H, s), 5.30 (1H, s), 5.40-6.00 (1H, m), 7.10-7.80 (5H, m), 8.45 (1H, s)
Elementary analysis for C.sub.19 H.sub.21 N.sub.3 O.sub.5 : Calcd. (%): C,61.44: H,5.70; N,11.32 Found (%): C,61.21: H,5.55: N,11.12
EXAMPLE 72
Preparation of n-hexyl 2,6-dimethyl-3-allylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Hexyl o-nitrobenzylideneacetoacetate (16.0 g, 0.05 mole) and 3-aminocrotonic allylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.2 g, yield 64.1%) as yellow prisms, m.p. 148.degree.-150.degree. C.
IR (KBr, cm.sup.-1): 1680, 1525, 1360
NMR (DMSO, .delta.: ppm): 0.60-1.60 (11H, m), 2.05 (3H, s), 2.25 (3H, s), 3.50-4.00 (4H, m), 4.70-4.90 (1H, m), 5.00 (1H, s), 5.35 (1H, s), 5.50-6.00 (1H, m), 7.10-7.80 (4H, m), 8.40 (1H, s)
Elementary analysis for C.sub.24 H.sub.31 N.sub.3 O.sub.5 : Calcd. (%): C,65.28: H,7.08: N,9.52 Found (%): C,65.00: H,6.95; N,9.4
EXAMPLE 73
Preparation of n-heptyl 2,6-dimethyl-3-allylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Heptyl o-nitrobenzylideneacetoacetate (16.7 g, 0.05 mole) and 3-aminocrotonic allylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.1 g, yield 61.7%) as yellow prisms, m.p. 118.degree.-120.degree. C.
IR (KBr, cm.sup.-1): 1680, 1525, 1360
NMR (DMSO, .delta.: ppm): 0.60-1.70 (13H, m), 2.05 (3H, s), 2.20 (3H, s), 3.50-4.00 (4H, m), 4.60-4.85 (1H, m), 4.95 (1H, s), 5.32 (1H, s), 5.40-6.00 (1H, m), 7.05-7.70 (5H, m), 8.33 (1H, s)
Elementary analysis for C.sub.25 H.sub.33 N.sub.3 O.sub.5 : Calcd. (%): C,65.91: H,7.30: N,9.23 Found (%) C,65.96: H,7.27: N,9.18
EXAMPLE 74
Preparation of n-octyl 2,6-dimethyl-3-allylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Octyl o-nitrobenzylideneacetoacetate (17.4 g, 0.05 mole) and 3-aminocrotonic allylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (12.3 g, yield 52.3%) as yellow prisms, m.p. 98.degree.-100.degree. C.
IR (KBr, cm.sup.-1): 1690, 1520, 1355
NMR (DMSO, .delta.: ppm): 0.60-1.70 (15H, m), 2.05 (3H, s), 2.22 (3H, s), 3.50-4.00 (4H, m), 4.65-4.90 (1H, m), 5.00 (1H, s), 5.38 (1H, s), 5.50-6.00 (1H, m), 7.10-7.80 (5H, m), 8.42 (1H, s)
Elementary analysis for C.sub.26 H.sub.35 N.sub.3 O.sub.5 : Calcd. (%): C,66.50: H,7.51; N,8.95 Found (%): C,66.79: H,7.47: N,8.72
EXAMPLE 75
Preparation of n-nonyl 2,6-dimethyl-3-allylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Nonyl o-nitrobenzylideneacetoacetate (18.1 g, 0.05 mole) and 3-aminocrotonic allylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (12.3 g, yield 50.9%) as yellow prisms, m.p. 100.degree.-102.degree. C.
IR (KBr, cm.sup.-1): 1675, 1525, 1360
NMR (DMSO, .delta.: ppm): 0.60-1.60 (17H, m), 2.05 (3H, s), 2.20 (3H, s), 3.40-4.00 (4H, m), 4.60-4.85 (1H, m), 4.95 (1H, s), 5.35 (1H, s), 5.40-6.00 (1H, m), 7.05-7.75 (5H, m), 8.38 (1H, s)
Elementary analysis for C.sub.27 H.sub.37 N.sub.3 O.sub.5 : Calcd. (%): C,67.05; H,7.71; N,8.69 Found (%): C,66.92: H,7.73: N,8.45
EXAMPLE 76
Preparation of methyl 2,6-dimethyl-3-propargylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
Methyl o-nitrobenzylideneacetoacetate (12.5 g, 0.05 mole) and 3-aminocrotonic propargylamide (6.9 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (15.3 g, yield 82.9%) as yellow prisms, m.p. 89.degree.-91.degree. C.
IR (KBr, cm.sup.-1): 1710, 1515, 1355
NMR (DMSO, .delta.: ppm): 2.08 (3H, s), 2.19 (3H, s), 2.75-3.00 (1H, m), 3.33 (3H, s), 3.60 (2H, m), 5.25 (1H, s), 7.05-7.90 (5H, m), 8.45 (1H, s)
Elementary analysis for C.sub.19 H.sub.19 N.sub.3 O.sub.5.1/4C.sub.2 H.sub.5 OH: Calcd. (%) C,61.49: H,5.42: N,11.03 Found (%): C,61.78: H,5.53: N,10.89
EXAMPLE 77
Preparation of n-heptyl 2,6-dimethyl-3-propargylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Heptyl o-nitrobenzylideneacetoacetate (16.7 g, 0.05 mole) and 3-aminocrotonic propargylamide (6.9 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisturc meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.9 g, yield 66.9%) as yellow prisms, m.p. 109.degree.-111.degree. C.
IR (KBr, cm.sup.-1): 1685, 1520, 1350
NMR (DMSO, .delta.: ppm): 0.60-1.60 (13H, m), 2.00 (3H, s), 2.20 (3H, s), 2.70-3.00 (1H, m), 3.60-4.00 (4H, m), 5.30 (1H, s), 7.00-7.90 (5H, m), 8.35 (1H, s)
Elementary analysis for C.sub.25 H.sub.31 N.sub.3 O.sub.5.1/10C.sub.2 H.sub.5 OH: Calcd. (%): C,66.06: H,6.95; N,9.17 Found (%): C,66.36: H,6.84: N,8.86
EXAMPLE 78
Preparation of n-octyl 2,6-dimethyl-3-propargylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Octyl o-nitrobenzylideneacetoacetate (17.4 g, 0.05 mole) and 3-aminocrotonic propargylamide (6.9 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. The residue is dissolved in elution solvent [chloroform:carbon tetrachloride:ethyl formate:formic acid:ethanol (10:10:8:1:2)] (30 ml) and subjected to column chromatography [silica gel 60 Art. 9385 (Manufactured by Merck Co.), 600 g, .phi.b 40 mm.times.100 cm]. The fraction containing the desired compound is regulated to pH 10 with 28% aqueous ammonia, and the organic layer is separated, washed with water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue is recrystallized from 80% ethanol to give the title compound (15.4 g, yield 67.4%) as yellow prisms, m.p. 85.degree.-87.degree. C.
IR (KBr, cm.sup.-1): 1670, 1520, 1355
NMR (DMSO, .delta.:ppm): 0.60-1.70 (15H, m), 2.05 (3H, s), 2.22 (3H, s), 2.80-3.00 (1H, m), 3.60-4.00 (4H, m), 5.35 (1H), 7.10-8.00 (5H, m), 8.45 (1H, s)
Elementary analysis for C.sub.26 H.sub.33 N.sub.3 O.sub.5.1/6C.sub.2 H.sub.5 OH: Calcd. (%): C,66.55; H,7.21: N,8.84 Found (%): C,66.83: H,7.13: N,8.53
EXAMPLE 79
Preparation of n-nonyl 2,6-dimethyl-3-propargylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Nonyl o-nitrobenzylideneacetoacetate (18.1 g, 0.05 mole) and 3-aminocrotonic propargylamide (6.9 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. The residue is dissolved in elution solvent [chloroform:carbon tetrachloride:ethyl formate:formic acid:ethanol (10:10:8:1:2)] (30 ml) and subjected to column chromatography [silica gel 60 Art. 9385 (Manufactured by Merck Co.), 600 g, .phi.40 mm.times.100 cm]. The fraction containing the desired compound is regulated to pH 10 with 28% aqueous ammonia, and the organic layer is separated, washed with water, dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue is recrystallized from 80% ethanol to give the title compound (14.0 g, yield 59.2%) as yellow prisms, m.p. 55.degree.-57.degree. C.
IR (KBr, cm.sup.-1): 1670, 1520, 1355
NMR (DMSO, .delta.: ppm): 0.60-1.70 (17H, m), 2.20 (3H, s), 2.22 (3H, s), 2.80-3.00 (1H, m), 3.60-4.00 (4H, m), 5.35 (1H, s), 7.10-8.00 (5H, m), 8.45 (1H, s)
Elementary analysis for C.sub.27 H.sub.35 N.sub.3 O.sub.5 : Calcd. (%): C,67.34: H,7.33; N,8.73 Found (%): C,67.25: H,7.23: N,8.72
EXAMPLE 80
Preparation of methyl 2,6-dimethyl-3-cyclopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
Methyl o-nitrobenzylideneacetoacetate (12.5 g, 0.05 mole) and 3-aminocrotonic cyclopropylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.6 g, yield 78.9%) as yellow prisms, m.p. 160.degree.-162.degree. C.
IR (KBr, cm.sup.-1): 1700, 1530, 1355
NMR (DMSO, .delta.: ppm): 0.20-0.70 (4H, m), 2.00 (3H, s), 2.15 (3H, s), 2.35-2.70 (1H, m), 3.30 (3H, s), 5.15 (1H, s), 7.00-7.60 (5H, m), 8.35 (1H, s)
Elementary analysis for C.sub.19 H.sub.21 N.sub.3 O.sub.5 : Calcd. (%): C,61.44: H,5.70: N,11.32 Found (%): C,61.17: H,5.74: N,11.25
EXAMPLE 81
Preparation of n-heptyl 2,6-dimethyl-3-cyclopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Heptyl o-nitrobenzylideneacetoacetate (16.2 g, 0.05 mole) and 3-aminocrotonic cyclopropylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.5 g, yield 63.4%) as yellow prisms, m.p. 103.degree.-106.degree. C.
IR (KBr, cm.sup.-1): 1700, 1520, 1355
NMR (DMSO, .delta.: ppm): 0.20-1.70 (17H, m), 2.00 (3H, s), 2.22 (3H, s), 2.35-2.80 (1H, m), 3.60-4.00 (2H, m), 5.30 (1H, s), 7.10-7.80 (5H, m), 8.38 (1H, s)
Elementary analysis for C.sub.25 H.sub.33 N.sub.3 O.sub.5 : Calcd. (%): C,65.91: H,7.30: N,9.23 Found (%): C,65.88; H,7.40: N,9.03
Example 82
Preparation of n-octyl 2,6-dimethyl-3-cyclopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Octyl o-nitrobenzylideneacetoacetate (17.4 g, 0.05 mole) and 3-aminocrotonic cyclopropylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (19.1 g, yield 81.3%) as yellow prisms, m.p. 104.degree.-106.degree. C.
IR (KBr, cm.sup.-1) 1700, 1520, 1360
NMR (DMSO, .delta.: ppm): 0.20-1.70 (19H, m), 2.00 (3H, s), 2.20 (3H, s), 2.35-2.80 (1H, m), 3.60-4.00 (2H, m), 5.27 (1H, s), 7.05-7.75 (5H, m), 8.33 (1H, s)
Elementary analysis for C.sub.26 H.sub.35 N.sub.3 O.sub.5 : Calcd. (%): C,66.50; H,7.51: N,8.95 Found (%): C,66.58: H,7.50: N,9.04
EXAMPLE 83
Preparation of n-nonyl 2,6-dimethyl-3-cyclopropylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Nonyl o-nitrobenzylideneacetoacetate (18.1 g, 0.05 mole) and 3-aminocrotonic cyclopropylamide (7.0 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (19.1 g, yield 78.9%) as yellow prisms, m.p. 110.degree.-112.degree. C.
IR (KBr, cm.sup.-1): 1695, 1520, 1355
NMR (DMSO, .delta.: ppm): 0.20-1.60 (21H, m), 2.03 (3H, s), 2.22 (3H, s), 2.40-2.80 (1H, m), 3.60-4.00 (2H, m), 5.30 (1H, s), 7.10-7.80 (5H, m), 8.41 (1H, s)
Elementary analysis for C.sub.27 H.sub.37 N.sub.3 O.sub.5 : Calcd. (%): C,67.05: H,7.71: N,8.69 Found (%): C,67.07: H,7.82: N,8.61
EXAMPLE 84
Preparation of methyl 2,6-dimethyl-3-cyclopentylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
Methyl o-nitrobenzylideneacetoacetate (12.5 g, 0.05 mole) and 3-aminocrotonic cyclopentylamide (8.4 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diethyl ether, and the precipitated crystals are separated by filtration and recrystallized from ethanol to give the title compound (13.2 g, yield 66.0%) as yellow prisms, m.p. 239.degree.-241.degree. C.
IR (KBr, cm.sup.-1): 1685, 1525, 1355
NMR (DMSO, .delta.: ppm): 1.00-1.90 (8H, m), 2.08 (3H, s), 2.18 (3H, s), 3.32 (3H, s), 3.60-4.10 (1H, m), 5.20 (1H, s), 7.00-7.70 (5H, m), 8.35 (1H, s)
Elementary analysis for C.sub.21 H.sub.25 N.sub.3 O.sub.5 : Calcd. (%): C,63.14: H,6.31: N,10.52 Found (%): C,63.18: H,6.27: N,10.27
EXAMPLE 85
Preparation of n-heptyl 2,6-dimethyl-3-cyclopentylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Heptyl o-nitrobenzylideneacetoacetate (16.7 g, 0.05 mole) and 3-aminocrotonic cyclopentylamide (8.4 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.3 g, yield 59.1%) as yellow prisms, m.p. 164.degree.-166.degree. C.
IR (KBr, cm.sup.-1): 1675, 1525, 1360
NMR (DMSO, .delta.: ppm): 0.60-1.80 (21H, m), 2.03 (3H, s), 2.20 (3H, s), 3.50-4.20 (3H, m), 5.35 (1H, s), 7.10-7.80 (5H, m), 8.35 (1H, s)
Elementary analysis for C.sub.27 H.sub.37 N.sub.3 O.sub.5 : Calcd. (%): C, 67.05: H, 7.71: N, 8.69 Found (%): C, 67.04: H, 7.81; N, 8.52
EXAMPLE 86
Preparation of n-octyl 2,6-dimethyl-3-cyclopentylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Octyl o-nitrobenzylideneacetoacetate (17.4 g, 0.05 mole) and 3-aminocrotonic cyclopentylamide (8.4 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (14.8 g, yield 59.6%) as yellow prisms, m.p. 151.degree.-153.degree. C.
IR (KBr, cm.sup.-1): 1675, 1520, 1355
NMR (DMSO, .delta.: ppm): 0.60-1.85 (23H, m), 2.03 (3H, s), 2.20 (3H, s), 3.50-4.20 (3H, m), 5.34 (1H, s), 7.10-7.75 (5H, m), 8.37 (1H, s)
Elementary analysis for C.sub.28 H.sub.39 N.sub.3 O.sub.5 : Calcd. (%): C,67.58: H,7.90: N,8.44 Found (%): C,67.46; H,7.94; N,8.27
EXAMPLE 87
Preparation of n-nonyl 2,6-dimethyl-3-cyclopentylaminocarbonyl-4-(o-nitrophenyl)-1,4-dihydropyridine-5-carboxylate:
n-Nonyl o-nitrobenzylideneacetoacetate (18.1 g, 0.05 mole) and 3-aminocrotonic cyclopentylamide (8.4 g, 0.05 mole) are dissolved in benzene (60 ml), and the mixture is refluxed for 7 hours. The produced water is removed by azeotropic distillation. After the stoichiometric amount of water is removed, which is measured by taking the water with a moisture meter, the reaction is stopped.
After completion of the reaction, the solvent is distilled off under reduced pressure. To the residue is added diisopropyl ether, and the precipitated crystals are separated by filtration and recrystallized from 80% ethanol to give the title compound (18.5 g, yield 72.3%) as yellow prisms, m.p. 154.degree.-156.degree. C.
IR (KBr, cm.sup.-1): 1675, 1525, 1360
NMR (DMSO, .delta.: ppm): 0.55-1.80 (25H, m), 2.05 (3H, s), 2.19 (3H, s), 3.55-4.10 (3H, m), 5.30 (1H, s), 7.00-7.70 (5H, m), 8.33 (1H, s)
Elementary analysis for C.sub.29 H.sub.41 N.sub.3 O.sub.5 : Calcd. (%): C, 68.08: H, 8.08: N, 8.21 Found (%): C, 68.29: H, 8.15: N, 8.14
EXAMPLES 88 TO 105
In the same manner as described in Examples 80 to 87, the compounds are shown in Table 3 are prepared, wherein the compounds have the NO.sub.2 group at ortho-position.
TABLE 3______________________________________ AppearanceEx. M.p. (solvent for re-No. R.sup.1 R.sup.2 (.degree.C.) crystallization)______________________________________88 ##STR17## C.sub.2 H.sub.5 201-203 Orange prisms (ethanol)89 " C.sub.3 H.sub.7 (n) 209-210 "90 " C.sub.3 H.sub.7 (iso) 199-201 "91 " C.sub.4 H.sub.9 (n) 178-180 Yellow prisms (ethanol)92 " C.sub.4 H.sub.9 (iso) 214-216 "93 " C.sub.5 H.sub.11 (n) 169-171 "94 " C.sub.5 H.sub.11 (iso) 190-192 Orange prisms (ethanol)95 " C.sub.6 H.sub.13 (n) 122-124 Yellow prisms (ethanol)96 " C.sub.6 H.sub.13 (iso) 164-166 "97 ##STR18## C.sub.2 H.sub.5 204-206 Orange prisms (ethanol)98 " C.sub.3 H.sub.7 (n) 189-191 Yellow prisms (ethanol)99 " C.sub.3 H.sub.7 (iso) 202-204 Orange prisms (ethanol)100 ##STR19## C.sub.4 H.sub.9 (n) 194-196 Yellow prisms (ethanol)101 " C.sub.4 H.sub.9 (iso) 199-201 Orange prisms (ethanol)102 " C.sub.5 H.sub.11 (n) 198-200 Yellow prisms (ethanol)103 " C.sub.5 H.sub.11 (iso) 202-204 "104 " C.sub.6 H.sub.13 (n) 185-187 "105 " C.sub.6 H.sub.13 (iso) 202-204 "______________________________________
Experiment 1-1
Hypolensive activity:
[Method]:
Spontaneously hypertensive male rats (13-15 week age, one group: 3 rats) were used. The rats had a maximum systolic blood pressure of about 200 mmHg and a mean blood pressure of about 180 mmHg. The rats were fixed in a Howlman cage without fasting, and the femoral arterial pressure was measured by a direct method without anesthesia with a cannula which was previously inserted into the femoral artery of the animal, via a pressure transducer (MPU-0.5, manufactured by Nippon Koden K.K.). The test compounds were orally administered in the form of a suspension in 0.5% methyl cellulose solution in a dose of 10 mg/kg (in some compounds, 3 mg/kg). In the control group, only 0.5% methyl cellulose solution was administered likewise. The blood pressure was measured for 5 hours after the administration of test compounds.
[Results]:
The hypotensive activity of the test compounds (difference of the mean blood pressure before and after the administration of test compounds) is shown in Table 4.
The test compounds are shown in Example number as to the compounds of this invention, and the reference compounds A, B, C, D and E are as shown hereinbefore.
TABLE 4__________________________________________________________________________Test Maximum Time until reaching Time for recovering Recoveringcompd. No. hypotension to max. hypotension 1/2 of max. hypotension time(Ex. No.) (mmHg) (minute) (hour) (hour)__________________________________________________________________________1 78 30 >5.0 >5.02' 55 30 5.0 >5.03 91 30 >5.0 >5.03' 60 30 >5.0 >5.05 70 15 5.0 >5.06 57 15 3.5 5.07 45 30 5.0 >5.08 30 15 4.0 5.043 68 15 2.5 5.044 60 15 2.5 4.045 15 15 0.5 1.546 10 15 0.5 1.547 32 30 2.0 3.051 40 30 3.0 >5.052 12 15 0.5 1.063 7 15 1.0 1.564 57 30 2.0 5.065 50 30 1.5 2.568 5 15 0.5 1.0A 49 15 1.5 4.0B 57 15 >5.0 >5.0C 20 15 1.5 2.0E 5 15 0.5 1.0__________________________________________________________________________ [Note]: In case of 2' and 3' the dose was 3 mg/kg.
As is shown in Table 4, among the compounds of this invention, alkyl 3-isopropylaminocarbonyl-4-(o-nitrophenyl)1,4-dihydropyridine-5-carboxylates (compounds of Example Nos. 1-3, 5-8, 43 and 44) showed particularly high hypotensive activity. Besides, the compounds of Example Nos. 1, 2, 3, 5 and 7 showed the same or more potent activity with longer duration in comparison with known 1,4-dihydropyridine compounds (Compound A: nifedipine, and Compound B: nicardipine hydrochloride).
Experiment 1-2
Hypotensive activity:
[Method]:
The hypotensive activity was measured in the same manner as described in Experiment 1-1 except that the rats were used in 3-5 rats per each group, and the test compounds were administered in a dose of 1 mg/kg (some compounds, 3 mg/kg), and the blood pressure was measured for 8 hours after the administration of test compounds.
[Results]:
The results are shown in Table 5.
TABLE 5__________________________________________________________________________ Maximum Time until reaching Time for recovering RecoveringTest compounds hypotension to max. hypotension 1/2 of max. hypotension timeEx. No. Dose (mmHg) (minute) (hour) (hour)__________________________________________________________________________78 1 mg/kg 33 60 3.0 5.079 " 45 60 3.0 5.082 " 48 180 >8.0 >8.083 " 61 180 >8.0 >8.0A 1 mg/kg 55 30 2.0 3.0-4.0B 3 mg/kg 27 30 2.0 3.0-4.0__________________________________________________________________________
As is shown in Table 5, the compounds of this invention (compounds of Example Nos. 78-79, and 82-83) showed the same or more potent hypotensive activity with longer duration in comparison with known Compound A (nifedipine) and Compound B (nicardipine hydrochloride).
Experiment 2-1
Activity on isolated heart:
[Method]:
Japanese white rabbit (weighing 2.2-2.5 kg) was anesthetized by introvenous injection of nembutal (20 mg/kg) and then sacrificed by bleeding from common carotid artery. Immediately, the heart was isolated and fixed to a Rangendorff's heart perfusion apparatus (KN-206 type, manufactured by Natsume Seisakusho, Japan) and perfused by Krebs-Henseleite solution (32.degree..+-.0.5.degree. C., 95% O.sub.2 +5% CO.sub.2) at a constant pressure of 45 cm H.sub.2 O. After stabilizing the heart preparation for 90 minutes, the test compound was administered. There were measured the perfusion volume with a drop-counting meter (ET-600G type, manufactured by Nippon Koden K.K.) and the heart pulse and the contractility via a force-displacement transducer (FD pick up, SB-IT type, manufactured by Nippon Koden K.K.) (for measuring heart pulse, an instant pulse meter (AT-601G type, minufactured by Nippon Koden K.K.) being further used).
The test compounds were dissolved in ethanol, and the solution was diluted in 100-fold with purified water, and the diluted solution was administered in an amount of 0.1 ml/heart (i.e. 3 .mu.g/heart).
The results of the test in the isolated heart sample are shown in Table 6.
TABLE 6______________________________________Test Increase of Reducing rate Inhibitory rateCompd No. coronary per- of heart pulse of systole(Ex. No.) fusion (%) (%) (%)______________________________________1 25 15 402 17 25 503 40 20 555 28 25 156 35 13 257 45 25 308 35 5 1340 25 1 1443 35 40 3544 30 16 2045 0 0 046 14 3 947 35 11 551 40 25 3052 20 15 4562 20 6 264 12 4 065 8 8 566 16 13 1568 29 11 6A 40 10 35B 15 5 10C 16 7 17D 20 5 15E 0 1 0______________________________________
As is shown in Table 6, the components of this invention (compounds of Example Nos. 3, 5 and 7) showed the same or more potent coronary vasodilating activity with longer duration in comparison with known 1,4-dihydropyridine compounds (nifedipine and nicardipine hydrochloride, etc.). Besides, the compounds of Example Nos. 1, 2, 3, 7 and 52 showed also moderate inhibitions on the heart pulse and contactility, and hence, these are also useful for the treatment of the diseases accompanied with arrhythmia or angina pectoris.
Experiment 2-2
Activity onto the isolated heart:
The activity was measured in the same manner as described in Experiment 2-1 except that in some test compounds, the dose was in 1 .mu.g/heart. Besides, the duration of the activity was evaluated by counting the time until the coronary perfusion volume became to the initial level before the administration of the test compound.
[Results]:
The results are shown in Table 7.
TABLE 7______________________________________Test Reducing InhibitoryCompd. Coronary perfusion rate of rate ofNo. Increase Duration heart systole(Ex. No.) (%) (minute) pulse (%) (%)______________________________________ 78* 55 60 10 35 79* 50 60 30 4080 25 <10 5 1581 15 10-15 0 1582 39 >120 25 3083 42 >120 20 50 84* 30 20-30 20 15 86* 50 60 20 15 87* 40 60 5 1588 35 <10 30 3089 30 <10 30 3590 15 <10 5 1091 20 <10 10 3592 10 <10 5 1093 20 20 15 2094 15 <10 0 1095 20 10-15 10 1596 20 <10 0 10A 40 <10 10 35B 15 <10 5 10______________________________________ [Note]: *These were used in a dose of 1 .mu.g/heart.
As is shown in Table 7, the compounds of this invention (compounds of Example Nos. 78-84 and 86-96) showed potent coronary vasodilating activity. Particularly, the compounds of Example Nos. 78, 79, 82-84, 86 and 87 showed more potent coronary vasodilating activity with longer duration in comparison with known Compound A (nifedipine) and Compound B (nicardipine hydrochloride), and further showed also temperate inhibitions on the heart pulse and contactility, and hence, these are also useful for the treatment of arrhythmia or angina pectoris accompanied with arrhythmia.
Experiment 3
Relaxing activity on the isolated aorta:
[Method]:
Japanese white rabbit (weighing 2.3-2.7 kg) was sacrificed by bleeding from common carotid artery. Immediately, the aorta was isolated and cut into a sprial strip. The strip preparation was vertically suspended under a resting tension of 2.0 g in a tissue bath containing 20 ml of modified Ringer solution while bubbling with a mixture of 95% O.sub.2 +5% CO.sub.2 by connecting one end of the strip to a lever of the above-mentioned FD pick up. The aortic strip was contracted with 30 mM KCl. When the contraction became constant, the test compound was accumulatively administered, and the relaxing effect was measured. After the final treatment, 10.sup.-4T M papaverine was administered and the maximum relaxation obtained thereby was taken as 100%. In comparison with the maximum relaxation obtained by papaverine, the rate of relaxation by the test compounds was evaluated, and the concentration of the test compounds for obtaining 50% relaxation (EC.sub.50) was calculated.
The test compound was dissolved in ethanol, and the solution was diluted in 100 to 1.times.10.sup.4 folds with a nutrient solution, and the diluted solution was administered.
[Result]:
The relaxing activity of the test compounds on the isolated aorta is shown in Table 8.
TABLE 8______________________________________Test Testcompd. No. compd. No.(Ex. No.) EC.sub.50 (M) (Ex. No.) EC.sub.50 (M)______________________________________1 5.8 .times. 10.sup.-7 45 1.7 .times. 10.sup.-72 3.0 .times. 10.sup.-7 46 7.0 .times. 10.sup.-83 1.8 .times. 10.sup.-7 47 2.0 .times. 10.sup.-85 2.0 .times. 10.sup.-8 50 7.0 .times. 10.sup.-76 1.2 .times. 10.sup.-8 51 1.3 .times. 10.sup.-77 1.3 .times. 10.sup.-7 52 4.2 .times. 10.sup.-78 3.0 .times. 10.sup.-8 62 1.5 .times. 10.sup.-79 6.7 .times. 10.sup.-7 64 1.5 .times. 10.sup.-710 4.0 .times. 10.sup.-7 65 1.3 .times. 10.sup.-711 3.2 .times. 10.sup.-7 66 7.0 .times. 10.sup.-816 6.1 .times. 10.sup.-7 68 1.0 .times. 10.sup.-718 7.1 .times. 10.sup.-7 69 5.7 .times. 10.sup.- 719 8.8 .times. 10.sup.-7 82 4.4 .times. 10.sup.-733 3.1 .times. 10.sup.-8 83 2.9 .times. 10.sup.-739 4.0 .times. 10.sup.-841 1.3 .times. 10.sup.-7 A 4.1 .times. 10.sup.-842 3.8 .times. 10.sup.-7 B 1.9 .times. 10.sup.-843 1.8 .times. 10.sup.-8 C >10.sup.-644 1.7 .times. 10.sup.-8 E >10.sup.-6______________________________________
As is shown in Table 8, the compounds of this invention (compounds of Example Nos. 5, 6, 8, 33, 39, 43, 44, 46, 47 and 66) showed the same or more potent activity as the known 1,4-dihydropyridine compounds (nifedipine and nicardipine hydrochloride, etc.). Besides, the compounds of Example Nos. 1, 2, 3, 7, 82 and 83 showed somewhat weak vasodilating activity but potent hypotensive activity as shown in Tables 4 and 5. Thus, these compounds may have also other hypotensive activities.
Experiment 4-1
Acute toxicity:
Wistar male rats (5 week age, weighing 105-135 g) were used. The compounds of Example Nos. 2, 3 and 7 were each orally administered to the animals in the form of a suspension in 0.5% methyl cellulose solution. The animals were observed for 7 days, and the 50% lethal dose (LD50) was calculated. The results are shown in Table 9.
TABLE 9______________________________________Test compd. No.(Example No.) LD.sub.50 (mg/kg)______________________________________2 100> >103 1000> >5007 >1000______________________________________
Experiment 4-2
Acute toxicity:
Wistar male and female rats (4 week age) and ddy male and female mice (4 week age) were used. The compounds of Example Nos. 82 and 83 were each orally administered to cellulose solution. The animals were observed for 7 days, and the 50% lethal dose (LD.sub.50) was calculated. The results are shown in Table 10.
TABLE 10______________________________________ LD.sub.50 (mg/kg)Test compd. No. Rats Mice(Example No.) Male Female Male Female______________________________________82 320 50 1280 114083 500> >100 10.gtoreq. -- --______________________________________
Claims
  • 1. A compound of the formula: ##STR20## wherein R.sup.1 is isopropyl, an allyl, propargyl, or a cycloalkyl having 3 to 8 carbon atoms, and R.sup.2 is an alkyl selected from the group consisting of n-heptyl, n-octyl, n-nonyl and n-decyl.
  • 2. The compound according to claim 1 wherein the NO.sub.2 substituent is in the ortho-position.
  • 3. The compound according to claim 1 wherein R.sup.2 is n-heptyl, n-octyl, or n-nonyl.
  • 4. The compound according to claim 1 wherein R.sup.1 is cyclopropyl or cyclopentyl.
  • 5. The compound according to claim 4 wherein R.sup.2 is n-heptyl, n-octyl or n-nonyl.
  • 6. The compound according to claim 1 wherein R.sup.1 is an allyl or propargyl and R.sup.2 is n-heptyl, n-octyl or n-nonyl.
  • 7. A pharmaceutical composition having vasodilatory activity for the prophylaxis and treatment of circulatory diseases, which comprises as an active ingredient an effective amount of a compound of the formula: ##STR21## wherein R.sup.1 is isopropyl, an allyl, propargyl, or a cycloalkyl having 3 to 8 carbon atoms, and R.sup.2 is an alkyl selected from the group consisting of n-heptyl, n-octyl, n-nonyl and n-decyl, in admixture with a pharmaceutically acceptable carrier or diluent.
  • 8. The composition according to claim 7 wherein the NO.sub.2 substituent is in the ortho-position.
  • 9. The pharmaceutical composition according to claim 7 wherein R.sup.2 is n-heptyl, n-octyl or n-nonyl.
  • 10. The pharmaceutical composition according to claim 7 wherein R.sup.1 is cyclopropyl or cyclopentyl.
  • 11. The pharmaceutical composition according to claim 10 wherein R.sup.2 is n-heptyl, n-octyl or n-nonyl.
  • 12. The pharmaceutical composition according to claim 7 wherein R.sup.1 is allyl or propargyl and R.sup.2 is n-heptyl, n-octyl or n-nonyl.
Priority Claims (1)
Number Date Country Kind
60-235909 Oct 1985 JPX
Parent Case Info

This application is a file wrapper continuation of U.S. application Ser. No. 920,124, filed Oct. 17, 1986 now abandoned.

US Referenced Citations (1)
Number Name Date Kind
4472411 Hatayama et al. Sep 1984
Foreign Referenced Citations (7)
Number Date Country
2228377 Jan 1974 DEX
29989 Aug 1980 JPX
20953 May 1982 JPX
146565 Sep 1983 JPX
116267 Jul 1984 JPX
227860 Dec 1984 JPX
7255 Jan 1986 JPX
Continuations (1)
Number Date Country
Parent 920124 Oct 1986